Company Overview and News

0
Suven Life gets product patents from China, United States

2018-06-12 moneycontrol
Suven Life Sciences today said it has been granted a product patent by China and the US each for a new chemical entity (NCE) for treatment of disorders associated with neurodegenerative diseases. These patents are valid till 2034 and 2036, respectively, the company said in a BSE filing.
530239 SUVEN

0
Suven Life Sciences Limited - Press Release

2018-06-12 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
530239 SUVEN

0
Suven Life Sciences Limited - Press Release

2018-06-08 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
530239 SUVEN

26
Market Live: Sensex mildly lower; all sectoral indices in the red except Auto

2018-06-01 moneycontrol
Market Update: The market continued to be mildly under pressure amid consolidation, but European stocks are strong in trade after Italy agreed to form a government.
BAJAJ-AUTO 539150 513262 500325 GAYAPROJ RELIANCE TTQQY 530239 PNCINFRA 532977 SUVEN TATACHEM 531795 505200 532343 RIGD HEROMOTOCO 500477 500570 TATAMOTORS EICHERMOT 500770 RLNIY ASHOKLEY ECQRY TVSMOTOR IBN ATULAUTO 532767 532843 MRZUY AKLD 532500 500182 ICICIBANK FORTIS MARUTI 532174 HRTQY AKLS SSWL TTM

29
Market Live: Sensex mildly lower, Midcaps underperform; HDFC Bank drags, Eicher Motors dips 4%

2018-06-01 moneycontrol
Allahabad High Court on Power NPAs: Allahabad High Court has stayed the Reserve Bank of India’s February 12 circular on resolution on non-performing assets (NPAs) for the assets in the power sector.
BAJAJ-AUTO 539150 513262 GAYAPROJ TTQQY 530239 PNCINFRA 532977 SUVEN TATACHEM 531795 505200 533106 OIL HDFCBANK HEROMOTOCO 500477 500570 TATAMOTORS EICHERMOT 500770 ASHOKLEY ECQRY IBN ATULAUTO 532767 532843 MRZUY AKLD 532500 500182 ICICIBANK FORTIS HDB MARUTI 532174 500180 HRTQY AKLS SSWL TTM

23
Market Live: Nifty holds 10,700 amid consolidation; Bajaj Auto extends rally

2018-06-01 moneycontrol
Market Update: The market continued to be rangebound as investors digested better-than-expected Q4 GDP data, which shows India is the fastest growing economy, and shifted focus to global trade concerns, and the movement in crude oil prices & rupee.
BAJAJ-AUTO 539150 TTQQY 530239 PNCINFRA 532977 SUVEN TATACHEM 505200 533106 GRANULES OIL 532482 HEROMOTOCO 500477 500570 TATAMOTORS EICHERMOT 500770 ASHOKLEY ECQRY IBN 532843 MRZUY AKLD 532500 500182 ICICIBANK FORTIS MARUTI 532174 HRTQY AKLS TTM

0
Suven Life Sciences Limited - Press Release

2018-06-01 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
530239 SUVEN

0
Suven Life gets product patents from New Zealand, Norway

2018-05-22 thehindubusinessline
Suven Life Sciences on Tuesday said that it has been granted one product patent each from New Zealand and Norway corresponding to the new chemical entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases. These patents are valid through 2034 and 2027, respectively.
530239 SUVEN

0
Suven Life gets product patents from New Zealand, Norway

2018-05-22 livemint
New Delhi:Suven Life Sciences on Tuesday said it has been granted a product patent by New Zealand and Norway each corresponding to a new chemical entity (NCE) for treatment of disorders associated with neurodegenerative diseases.
530239 SUVEN

25
Market Live: Sensex consolidates; SBI shares rise despite posting big Q4 loss, Tata Motors top gainer

2018-05-22 moneycontrol
Market Update: The market continued to be rangebound as investors closely monitor earnings season, and the movement in oil prices and rupee.
513262 BHUSANSTL 517506 532978 530239 532712 S68 SUVEN TTKPRESTIG 500470 RCOM BJJQY 500570 500493 TATAMOTORS BHARATFORG 500055 500034 SBAZ SPXCF FLFL 536507 SPXCY BAJAJFINSV BAJFINANCE TTST TATASTEEL TATLY SSWL TTM

16
Market Live: Sensex consolidates ahead of SBI earnings; Bharat Forge drops post Q4 nos

2018-05-22 moneycontrol
Buzzing: Shares of TTK Prestige touched 52-week low of Rs 5,612, losing 2 percent intraday as company reported 32 percent fall in its Q4 (Jan-March) net profit at Rs 37.44 crore against Rs 55.3 crore in the same quarter last fiscal.
BAJAJ-AUTO 513262 DABUR 517506 530239 532977 532712 DBRQY GLKQY S68 SUVEN JUSTDIAL TTKPRESTIG 500096 535648 RCOM 523574 500493 BHARATFORG GLENMARK 523736 570002 SPXCF DPL FRL FLFL 536507 SPXCY 532296 FRLDVR JSTQY SSWL

0
Suven Life gets product patents from New Zealand, Norway

2018-05-22 moneycontrol
Suven Life Sciences today said it has been granted a product patent by New Zealand and Norway each corresponding to a new chemical entity (NCE) for treatment of disorders associated with neurodegenerative diseases.
530239 SUVEN

0
Suven Life Sciences rises 2% on product patents from New Zealand, Norway

2018-05-22 moneycontrol
Share price of Suven Life Sciences rose 2.5 percent intraday Tuesday as company secured product patents in New Zealand and Norway.
530239 SUVEN

0
Suven Life Sciences Limited - Press Release

2018-05-22 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
530239 SUVEN

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...